Mercado cerrado -
Otros sitios de cotización
|
Varia. Cinco días. | Varia. 1 de enero. | ||
1,54 USD | -1,28 % | 0,00 % | +79,28 % |
Resumen de negocios
Número de empleados: 138
Directores
Directores | Puesto | Edad | Desde |
---|---|---|---|
David Woodhouse
CEO | Chief Executive Officer | 54 | 02/03/15 |
William Rieflin
CHM | Chairman | 64 | 01/09/10 |
Daniel Kaplan
CTO | Chief Tech/Sci/R&D Officer | - | 01/01/08 |
William Chang
CTO | Chief Tech/Sci/R&D Officer | - | 01/02/19 |
Hsiao Lieu
CTO | Chief Tech/Sci/R&D Officer | 53 | 01/03/19 |
Valerie Pierce
CMP | Compliance Officer | 61 | 29/10/19 |
David Goeddel
BRD | Director/Board Member | 72 | 01/01/08 |
Joyce Q. Acbay
LAW | General Counsel | - | 01/04/20 |
Irene Perlich
AUD | Comptroller/Controller/Auditor | - | 01/03/21 |
Administradores
Administradores | Puesto | Edad | Desde |
---|---|---|---|
Roger Perlmutter
BRD | Director/Board Member | 71 | 08/06/21 |
David Goeddel
BRD | Director/Board Member | 72 | 01/01/08 |
William Rieflin
CHM | Chairman | 64 | 01/09/10 |
David Woodhouse
CEO | Chief Executive Officer | 54 | 02/03/15 |
Clase de acciones
Vote | Quantity | Flotante | Autocontrol | Total Float | |
---|---|---|---|---|---|
Acción A | 1 | 83 462 408 | 81 886 322 ( 98,11 %) | 0 | 98,11 % |
Información de la empresa
NGM Biopharmaceuticals, Inc.
333 Oyster Point Boulevard
94080-7014, South San Francisco
+650 243 5555
http://www.ngmbio.comSector
Varia. 1 de ene. | Capi. | |
---|---|---|
+79,28 % | 129 M | |
-2,31 % | 103 mil M | |
+0,56 % | 95,28 mil M | |
+1,69 % | 22,15 mil M | |
-17,37 % | 21,02 mil M | |
-9,30 % | 18,15 mil M | |
-41,01 % | 16,73 mil M | |
-14,85 % | 16,05 mil M | |
+3,21 % | 13,68 mil M | |
+33,54 % | 12,17 mil M |
- Bolsa de valores
- Acciones
- Acción NGM
- Empresa NGM Biopharmaceuticals, Inc.